- Raised $5.5M funding round, Feb 2014
- Raised $10M funding round, May 2013
- Raised $2M funding round, Jan 2016
About
Neuronix develops methods for modifying the course of treatment for Alzheimer's disease, offering the potential for long-term improvement in patient quality of life. The neuroAD system is based on the company's core noninvasive cortical enhancer technology and is CE marked for the treatment of mild to moderate Alzheimer's disease. The company's patented technology uses magnetic stimulation interlaced with cognitive training and directed at specific brain regions affected by Alzheimer's disease. This combination induces long-term potentiation, which is associated with learning and memory processes. Several published studies performed at the Beth Israel Deaconess Medical Center (Harvard Medical School, Massachusetts), in Israel, and in other locations showed statistically significant clinical results compared with placebo following six weeks of daily one-hour sessions. The neuroAD therapy system is CE marked for commercial use in Europe for the treatment of Alzheimer's disease. A multi-center clinical study was recently completed in the United States and will be used to support a submission seeking US FDA clearance. Neuronix is a privately held company with headquarters in Israel and subsidiaries in the United States and United Kingdom.
Funding history · 3 rounds · $17.5M total
Q&A
- What is Neuronix's primary focus?
- Neuronix develops methods for modifying the course of treatment for Alzheimer's disease, utilizing magnetic stimulation technology.
- What is the status of Neuronix?
- Neuronix is currently inactive and ceased to operate in April 2020.
- Where is Neuronix headquartered?
- Neuronix is headquartered in Yokne'am Illit, Israel.
- What is the neuroAD system?
- The neuroAD system is Neuronix's core noninvasive cortical enhancer technology, which is CE marked for the treatment of mild to moderate Alzheimer's disease.
- What is Neuronix's patented technology?
- Neuronix's patented technology uses magnetic stimulation interlaced with cognitive training directed at specific brain regions affected by Alzheimer's disease to induce long-term potentiation.
- What was the total amount of funding raised by Neuronix?
- Neuronix raised a total of $17,500,000 across multiple funding rounds.
- When was Neuronix's last reported funding round?
- Neuronix's last reported funding round was in January 2016, raising $2,000,000.
- How many employees did Neuronix have?
- Neuronix had an employee count in the 11-50 range.
Team · 1
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| facebook.com/Neuronix.neuroAD | |
| YouTube | youtube.com/channel/UCMQl2bPBC0hCTaDrHALoIGA |
Identifiers & details
| Founded | 2008-1 |
|---|---|
| Employees (exact) | 16 |
| Offices | Holliston |
| Status reason | Non Active, Apr 2020 ceased to operate |